# NGN Capital

> NGN Capital is a VC fund in New York backing Health Care and Biotechnology. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 24
- Last investment: Jul 2017
- Lead investor: 42%
- Last updated: Aug 2026
- Website: http://www.ngncapital.com

NGN Capital is a venture capital firm specializing in investments in the US and European healthcare sector. The fund focuses specifically on investments in the healthcare, pharmaceutical, and biotech sectors including drug products, medical devices, diagnostics, and healthcare services.

## Contacts

5 contacts available for NGN Capital. Shizune tracks 9 team members at NGN Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ngn-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 29% |
| Biotechnology | 7 | 29% |
| Medical Device | 4 | 17% |
| Pharmaceutical | 4 | 17% |
| Therapeutics | 3 | 13% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 7 | 29% |
| Series B | 5 | 21% |
| Series A | 2 | 8% |
| Series D | 2 | 8% |
| Series F | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 29% |
| Switzerland | 2 | 8% |
| Israel | 1 | 4% |
| Germany | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Noah J. Kroloff | Partner | 1 | — |
| Bernard Peperstraete | Partner | 0 | — |
| Ivica Cerina | Partner | 0 | — |
| Kenneth J. Gorelick | Venture Partner | 0 | — |
| Kenneth S. Abramowitz | Co-Founder & General Partner | 2 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Exosome Diagnostics | Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technologymakes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. | $30M | Series C | Jul 24, 2017 |  |
| Exosome Diagnostics | Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technologymakes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. | $16M | Series B | Jan 07, 2016 |  |
| Exosome Diagnostics | Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technologymakes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. | $17.6M | Series B | Sep 02, 2015 |  |
| Exosome Diagnostics | Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technologymakes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. | $27M | Series B | Mar 11, 2014 |  |
| Endosense | Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact forceduring the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation. | $43.6M | Series C | Nov 27, 2013 |  |
| Endosense | Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact forceduring the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation. | $40.3M | Series C | Nov 27, 2012 |  |
| Small Bone Innovations | Small Bones Innovations (SBi) makes devices for small bones and joints, particularly focusing on trauma and arthroplasty. | $15M | Series F | Dec 17, 2010 |  |
| Artisan Pharma | Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offersits products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts. | $3M | Series C | Jul 20, 2010 |  |
| Exosome Diagnostics | Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technologymakes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. | $20M | Series A | May 11, 2010 |  |
| Artisan Pharma | Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offersits products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts. | $22M | Series B | Mar 01, 2010 |  |

10 of 24 investments shown.

## Co-investors
- [3i Group](https://shizune.co/investors/profile/3i-group) — VC Fund, 6 deals together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 5 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 4 deals together
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund, 3 deals together
- [Neomed Management](https://shizune.co/investors/profile/neomed-management) — VC Fund, 3 deals together
- Viscogliosi Brothers — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does NGN Capital invest in?

NGN Capital invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series C and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact NGN Capital?

Public channels for NGN Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at NGN Capital?

The team at NGN Capital includes Noah J. Kroloff (Partner), Bernard Peperstraete (Partner) and Ivica Cerina (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co